A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (NCT06203210)

🧪 Interventions in This Study

• Ifinatamab deruxtecan (DRUG)
• Topotecan (DRUG)
• Amrubicin (DRUG)
• Lurbinectedin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (229 Sites)

Showing the first 25 of 229 sites.

• Highlands Oncology Group — Springdale, Arkansas
• Clinical Research Providence Medical Foundation — Fullerton, California
• UCLA Hematology-Oncology — Los Angeles, California
• UCSF Mission Bay Mission Hall — San Francisco, California
• University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center — Miami, Florida
• AdventHealth Orlando, Cancer Institute — Orlando, Florida
• H. Lee Moffitt Cancer Center and Research Institute, Inc — Tampa, Florida
• Rush MD Anderson Cancer Center — Chicago, Illinois
• Baptist Health Lexington — Lexington, Kentucky
• University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
• John Hopkins School of Medicine — Baltimore, Maryland
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Henry Ford Health System — Detroit, Michigan
• Mercy Clinic Oncology and Hematology Sindelar Cancer Center — St Louis, Missouri
• University of Nebraska Medical Center — Omaha, Nebraska
• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire
• Astera Cancer Care — East Brunswick, New Jersey
• Hackensack Meridian Health Jsumc — Neptune City, New Jersey
• Clinical Research Alliance, Inc — Lake Success, New York
• Laura and Isaac Perlmutter Cancer Center at NYU Langone Health Long Island — New York, New York
• New York University Cancer Center - Laura and Isaac — New York, New York
• Montefiore Medical Center Prime — The Bronx, New York
• Cleveland Clinic Mercy Hospital — Canton, Ohio
• Oncology/Hematology Care Clinical Trials, Llc — Cincinnati, Ohio
• Providence Portland Medical Center — Portland, Oregon

📞 Contact the Study Coordinator

Phone: (908) 992-6400

Email: CTRinfo@dsi.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Small Cell Lung Cancer

• Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy — New Haven, Connecticut
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) — Chandler, Arizona
• Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) — Irvine, California
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy — Tucson, Arizona
• Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms — Rockville, Maryland
• PF-07104091 as a Single Agent and in Combination Therapy — Clive, Iowa

Explore by condition: All Small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.